Eli Lilly’s key developments
Eli Lilly & Co. (LLY) has announced several developments since its second-quarter earnings call. We’ll touch on these key developments in this article.
Olumiant (baricitinib) was launched for the treatment of rheumatoid arthritis in the US markets.
- Eli Lilly (LLY) announced a potential initial public offering for Elanco, which is its animal health business.
- The company acquired ARMO Biosciences.
- Eli Lilly acquired AurKa Pharma.
- The company announced an agreement with Anima Biotech.
- LLY distributed ~$600.0 million in dividends to its shareholders.
- Eli Lilly repurchased ~$950.0 million in shares. The company exhausted the $5.0 billion share repurchase program and announced a new $8.0 billion share repurchase program.
- The FDA approved 2-mg Olumiant (baricitinib) for the treatment of rheumatoid arthritis.
- The FDA and CHMP (Committee for Medicinal Products for Human Use) approved a label update for Taltz (ixekizumab).
- The FDA approved a label update for Alimta (pemetrexed).
- The FDA approved a label update for Trulicity (dulaglutide).
- Eli Lilly submitted nasal glucagon for regulatory approval to the FDA and EMA (European Medicines Agency).
- Eli Lilly announced the discontinuation of its Phase 3 clinical trials for Lanabecestat with AstraZeneca (AZN). Lanabecestat is an oral BACE inhibitor for the treatment of patients with Alzheimer’s disease.
- The company announced that both trials in its EASE Phase 3 program evaluating Jardiance, as well as the CARMELINA trial for Tradjenta, met their primary endpoints. These drugs are being developed in collaboration with Boehringer Ingelheim.
- Eli Lilly announced that the Phase 3 study evaluating tanezumab for the treatment of patients with osteoarthritis met its primary endpoints. This study is part of its collaborative agreement with Pfizer (PFE).
- Eli Lilly announced that the COAST-W study evaluating Taltz for the treatment of ankylosing spondylitis met its primary endpoint and major secondary endpoints.